Altimmune Reports FY25 Financials: Why Is Big Pharma Staying Away [Seeking Alpha]
Altimmune, Inc. (ALT)
NASDAQ:AMEX Investor Relations:
altimmune.com/investors
Company Research
Source: Seeking Alpha
ALT secured $340M in cash, providing a 2.5-year runway to support late-stage clinical development and operational milestones. Despite FDA Breakthrough Therapy designation and strong Phase 2b data, ALT has not attracted strategic partnerships, raising competitive and execution concerns. Rapid GLP-1 commoditization and established competitors like Madrigal challenge ALT's differentiation and market entry timing. Tom Merton/OJO Images via Getty Images Thesis Altimmune, Inc. ( ALT ) has just reported a 4Q25 GAAP EPS of -$0.27, a figure which missed analyst expectations by about $0.03. Now, even with the earnings miss, the company did still manage to post some revenue, about This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensati
Show less
Read more
Impact Snapshot
Event Time:
ALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALT alerts
High impacting Altimmune, Inc. news events
Weekly update
A roundup of the hottest topics
ALT
News
- Altimmune (ALT) had its price target lowered by B. Riley Financial, Inc. from $18.00 to $13.00. They now have a "buy" rating on the stock.MarketBeat
- Altimmune Inc (ALT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Fortification [Yahoo! Finance]Yahoo! Finance
- Altimmune (ALT) had its "market perform" rating reaffirmed by William Blair.MarketBeat
- Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates [Yahoo! Finance]Yahoo! Finance
- Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business UpdatesGlobeNewswire
ALT
Earnings
- 3/5/26 - Miss
ALT
Sec Filings
- 3/6/26 - Form PRE
- 3/6/26 - Form 10-K
- 3/5/26 - Form 8-K
- ALT's page on the SEC website